PT  - JOURNAL ARTICLE
AU  - Yeh, Ting-Yu
AU  - Contreras, Gregory P.
TI  - Full vaccination against COVID-19 suppresses SARS-CoV-2 delta variant and spike gene mutation frequencies and generates purifying selection pressure
AID  - 10.1101/2021.08.08.21261768
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.08.08.21261768
4099  - http://medrxiv.org/content/early/2021/10/04/2021.08.08.21261768.short
4100  - http://medrxiv.org/content/early/2021/10/04/2021.08.08.21261768.full
AB  - COVID-19 vaccination resistance has become a major challenge to prevent global SARS-CoV-2 transmission. Here we report that the vaccination coverage rate is inversely correlated to the mutation frequency of the full genome (R2=0.878) and spike gene (R2=0.829) of SARS-CoV-2 delta variants in 16 countries, suggesting that full vaccination against COVID-19, with other mitigation strategies, is critical to suppress emergent mutations. Neutrality analysis of DH and Zeng’s E tests suggested that directional selection was the major driving force of delta variant evolution. To eliminate the homogenous effects (population expansion, selective sweep etc.), the synonymous (Dsyn) and nonsynonymous (Dnonsyn) polymorphisms of the delta variant spike gene were estimated with Tajima’s D statistic. Both D ratio (Dnonsyn/Dsyn) and ΔD (Dsyn-Dnonsyn) have positive correlation with the full vaccination rate (R2= 0.723 and 0.505, respectively) in 19 countries, indicating that purifying selection pressure of SARS-CoV-2 spike gene increased as the vaccination coverage rate increased. Taken together, our data suggests that vaccination plays an important role in the purifying selection force of spike protein of SARS-CoV-2 delta variants.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNot applicableFunding StatementNo fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No patients were involved and no IRB was required in this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yes1.The World Health organization. Tracking SARS-CoV-2 variants. 2. Global Initiative on Sharing All Influenza Data. 3. Coronavirus (COVID-19) Vaccinations. Our World in Data. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ https://www.gisaid.org/ https://ourworldindata.org/covid-vaccinations